Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit.

Autor: Farrokhpour M; Department of Internal Medicine, Firoozgar Medical and Educational Hospital, Iran University of Medical Sciences, Tehran, Iran., Rezaie N; Department of Internal Medicine, Firoozgar Medical and Educational Hospital, Iran University of Medical Sciences, Tehran, Iran., Moradi N; Department of Internal Medicine, Firoozgar Medical and Educational Hospital, Iran University of Medical Sciences, Tehran, Iran., Ghaffari Rad F; Department of Internal Medicine, Firoozgar Medical and Educational Hospital, Iran University of Medical Sciences, Tehran, Iran., Izadi S; Department of Internal Medicine, Firoozgar Medical and Educational Hospital, Iran University of Medical Sciences, Tehran, Iran., Azimi M; Department of Internal Medicine, Firoozgar Medical and Educational Hospital, Iran University of Medical Sciences, Tehran, Iran., Zamani F; Gastrointestinal and liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran., Izadi S; School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran., Ranjbar M; Antimicrobial Resistance Research Center, Iran University of Medical Sciences, Tehran, Iran., Jamshidi Makiani M; Antimicrobial Resistance Research Center, Iran University of Medical Sciences, Tehran, Iran., Laali A; Department of Infectious Diseases, Firoozgar Medical and Educational Hospital, Iran University of Medical Sciences, Tehran, Iran., Roham M; Antimicrobial Resistance Research Center, Iran University of Medical Sciences, Tehran, Iran., Yadollahzadeh M; Department of Internal Medicine, Firoozgar Medical and Educational Hospital, Iran University of Medical Sciences, Tehran, Iran.

Publikováno v: Archives of Iranian medicine [Arch Iran Med] 2021 Feb 01; Vol. 24 (2), pp. 139-143. Date of Electronic Publication: 2021 Feb 01.